These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 318989)
1. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Pinder RM; Brogden RN; Speight TM; Avery GS Drugs; 1977 Jan; 13(1):3-23. PubMed ID: 318989 [TBL] [Abstract][Full Text] [Related]
2. Dantrolene sodium: long-term effects in severe spasticity. Chyatte SB; Basmajian JV Arch Phys Med Rehabil; 1973 Jul; 54(7):311-5. PubMed ID: 4577936 [No Abstract] [Full Text] [Related]
3. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. Schmidt RT; Lee RH; Spehlmann R J Neurol Neurosurg Psychiatry; 1976 Apr; 39(4):350-6. PubMed ID: 778344 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of dantrolene sodium in the treatment of spasticity. Chipman M; Kaul S; Lambie M Dis Nerv Syst; 1974 Sep; 35(9):427-31. PubMed ID: 17894068 [TBL] [Abstract][Full Text] [Related]
5. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Glass A; Hannah A Paraplegia; 1974 Nov; 12(3):170-4. PubMed ID: 4616209 [No Abstract] [Full Text] [Related]
6. Dantrolene sodium: long-term effects in patients with muscle spasticity. Joynt RL Arch Phys Med Rehabil; 1976 May; 57(5):212-7. PubMed ID: 776122 [TBL] [Abstract][Full Text] [Related]
7. Effect of dantrolene sodium on the incidence of seizures in children with spasticity. Nogen AG Childs Brain; 1979; 5(4):420-5. PubMed ID: 378580 [TBL] [Abstract][Full Text] [Related]
8. [Dantrolene in juvenile spasticity: 3 months of daily observation]. Berruti P Riv Neurol; 1979; 49(1):30-52. PubMed ID: 451397 [TBL] [Abstract][Full Text] [Related]
10. Medical treatment for spasticity in children with cerebral palsy. Nogen AG Childs Brain; 1976; 2(5):304-8. PubMed ID: 798660 [TBL] [Abstract][Full Text] [Related]
11. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Ward A; Chaffman MO; Sorkin EM Drugs; 1986 Aug; 32(2):130-68. PubMed ID: 3527659 [TBL] [Abstract][Full Text] [Related]
12. [Attenuating effect of a new pharmacological agent (Dantrolene sodium) on spasticity]. Ladd HW; Gingras G; Boucher J; Kazdan N; Keenan R Union Med Can; 1973 May; 102(5):1087-92. PubMed ID: 4576244 [No Abstract] [Full Text] [Related]
13. [Dantrium in the treatment of increased muscle tonus in patients with multiple sclerosis]. Cendrowski W Neurol Neurochir Pol; 1977; 11(1):117-21. PubMed ID: 320494 [TBL] [Abstract][Full Text] [Related]
14. The effect of dantrolene sodium on spasticity in multiple sclerosis. Gelenberg AJ; Poskanzer DC Neurology; 1973 Dec; 23(12):1313-5. PubMed ID: 4796610 [No Abstract] [Full Text] [Related]
15. The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration. Meyler WJ; Bakker H; Kok JJ; Agoston S; Wesseling H J Neurol Neurosurg Psychiatry; 1981 Apr; 44(4):334-9. PubMed ID: 7241161 [TBL] [Abstract][Full Text] [Related]
17. Dantrolene sodium for treatment of spasticity. Med Lett Drugs Ther; 1974 Jul; 16(15):61-2. PubMed ID: 4843632 [No Abstract] [Full Text] [Related]
18. [Effect of Dantrium on spasticity in paraplegic and tetraplegic patients (author's transl)]. van Laere M; Leus P; Mastelinck C J Belge Med Phys Rehabil; 1978; 1(2):189-99. PubMed ID: 757420 [No Abstract] [Full Text] [Related]
19. [Pathogenetic therapy of spasticity]. Kasatkin DS Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):80-5. PubMed ID: 18697257 [No Abstract] [Full Text] [Related]
20. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Gracies JM; Nance P; Elovic E; McGuire J; Simpson DM Muscle Nerve Suppl; 1997; 6():S92-120. PubMed ID: 9826984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]